Atomoxetine provides stimulant-free alternative for ADHD. (FDA Approval).(Strattera for treatment of attention-deficit hyperactivity disorder )

Adults and children suffering from attention-deficit hyperactivity disorder now have a treatment specifically indicated for them.

Atomoxetine (Strattera) is the first drug to receive Food and Drug Administration approval for the treatment of attention-deficit hyperactivity disorder (ADHD) in both adults and children. It is also the first new type of drug approved for the disorder in 3 decades.

Data from six double-blind trials presented to the FDA--with 697 patients taking atomoxetine, 427 of whom were children and adolescents--found the drug to be significantly more effective than placebo.

Because it is not a stimulant, atomoxetine dodges a controlled substances classification, unlike stimulant medications now prescribed for …